Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Date publication

mai 2026

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimboaurg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42066233

Résumé

The antibody-drug conjugate Temab-A comprises the c-Met-targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion.

Référence

J Clin Oncol. 2026 05 1;:JCO2501525